Oral antimicrobial agents in patients with short bowel syndrome: worth a try!

Abstract Background The use of oral antimicrobial agents in patients with short bowel syndrome (SBS) is challenging due to the changes in gastrointestinal anatomy that may result in diminished absorption and altered drug bioavailability. Prospective studies evaluating bioavailability of antimicrobial agents after oral administration in SBS patients are lacking. Objectives To determine the bioavailability of orally administered antimicrobial agents commonly used for treatment in SBS patients to guide clinical decision making when faced with infections. Methods We performed an explorative, clinical study investigating the pharmacokinetics (PK) of clindamycin, ciprofloxacin, flucloxacillin and fluconazole in SBS patients with intestinal failure. Participants received a combination of two antimicrobial agents simultaneously. To determine the oral bioavailability, participants received a single oral and IV dose of both agents on two occasions, after which they underwent intensive PK sampling on six predefined time points up to 12 hours after administration. Primary outcome was the oral bioavailability of these antimicrobial agents. Secondary outcomes were intravenous PK characteristics following non-compartmental analysis. Results Eighteen SBS patients were included: the mean (SD) age was 59 (17) years and 61% of participants were female. The median observed (IQR) bioavailability of ciprofloxacin, clindamycin, flucloxacillin and fluconazole were 36% (24–50), 93% (56–106), 50% (32–76) and 98% (61–107), respectively. Conclusion The bioavailability of selected antimicrobial agents in certain patients with SBS appeared to be better than expected, providing a feasible treatment option. Due to the large observed differences between patients, therapeutic drug monitoring should be part of the treatment to safeguard adequate exposure in all patients. Trial registration Registered in the Dutch Trial Register (NL7796) and EudraCT number 2019-002587-28

[1]  M. Gompelman,et al.  Oral Antibiotics in Patients with Short Bowel Syndrome: Do or Don’t? , 2021, European Journal of Drug Metabolism and Pharmacokinetics.

[2]  L. S. Law,et al.  Changes of Drug Pharmacokinetics in Patients with Short Bowel Syndrome: A Systematic Review , 2021, European Journal of Drug Metabolism and Pharmacokinetics.

[3]  S. Geerlings,et al.  Pharmacokinetic-pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function. , 2020, International journal of antimicrobial agents.

[4]  J. V. van Dissel,et al.  The simplified oral flucloxacillin absorption test: an accurate method to identify patients with inadequate oral flucloxacillin absorption. , 2019, The Netherlands journal of medicine.

[5]  M. Soeters,et al.  Low circulating concentrations of citrulline and FGF19 predict chronic cholestasis and poor survival in adult patients with chronic intestinal failure: development of a Model for End-Stage Intestinal Failure (MESIF risk score). , 2019, The American journal of clinical nutrition.

[6]  S. Middeldorp,et al.  Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. , 2017, Thrombosis research.

[7]  J. Prins,et al.  A Systematic Review of Quality Indicators for Appropriate Antibiotic Use in Hospitalized Adult Patients , 2017, Infectious disease reports.

[8]  L. Pironi.  Definitions of intestinal failure and the short bowel syndrome. , 2016, Best practice & research. Clinical gastroenterology.

[9]  A. Van Gossum,et al.  ESPEN guidelines on chronic intestinal failure in adults. , 2016, Clinical nutrition.

[10]  M. Struelens,et al.  Prospective multicentre feasibility study of a quality of care indicator for intravenous to oral switch therapy with highly bioavailable antibiotics. , 2012, The Journal of antimicrobial chemotherapy.

[11]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Trials.

[12]  Nicola Ward.  The Impact of Intestinal Failure on Oral Drug Absorption: A Review , 2010, Journal of Gastrointestinal Surgery.

[13]  F. Muller,et al.  Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. , 2006, Methods and findings in experimental and clinical pharmacology.

[14]  B. Messing,et al.  Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. , 2000, Gastroenterology.

[15]  B. Schug,et al.  Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation. , 1999, International journal of clinical pharmacology and therapeutics.

[16]  B. Charles,et al.  Pharmacokinetics and Bioavailability of Flucloxacillin in Elderly Hospitalized Patients , 1995, Journal of clinical pharmacology.

[17]  B. Guglielmo,et al.  Systemic absorption of oral fluconazole after gastrointestinal resection. , 1994, The Journal of antimicrobial chemotherapy.

[18]  S. O'keefe,et al.  Recurrent sepsis in home parenteral nutrition patients: an analysis of risk factors. , 1994, JPEN. Journal of parenteral and enteral nutrition.

[19]  W. Ritschel,et al.  Gastrointestinal parameters that influence oral medications. , 1993, Journal of pharmaceutical sciences.

[20]  F. Cavataio,et al.  Case Report Extreme Short Bowel Syndrome: A Case for Reviewing the Guidelines for Predicting Survival , 1993, Journal of pediatric gastroenterology and nutrition.

[21]  J. Rotschafer,et al.  Clinical Pharmacokinetics of Ciprofloxacin , 1990, Clinical pharmacokinetics.

[22]  J. K. Faulkner,et al.  Pharmacokinetics and tissue penetration of fluconazole in humans. , 1990, Reviews of infectious diseases.

[23]  U. Fuhr,et al.  Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule). , 1989, The American journal of medicine.

[24]  J. Guggenbichler,et al.  Biovailability of oral antibiotics in children with short-bowel syndrome , 1984 .

[25]  H. Mattie,et al.  Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis. , 1975, British journal of clinical pharmacology.

[26]  David Moher,et al.  CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials , 2010, PLoS medicine.

[27]  G. Bongaerts,et al.  Enteral Drug Absorption in Patients with Short Small Bowel , 2004, Clinical pharmacokinetics.

[28]  American Gastroenterological Association medical position statement: short bowel syndrome and intestinal transplantation. , 2003, Gastroenterology.

[29]  E. Sagnelli,et al.  Pharmacokinetics of ciprofloxacin in impaired liver function. , 1989, International journal of clinical pharmacology research.

[30]  R. Parsons.  Drug Absorption in Gastrointestinal Disease With Particular Reference to Malabsorption Syndromes , 1977, Clinical pharmacokinetics.